GSK expands late-stage clinical trials with $2.52 billion cost-saving program
GSK GSK Plc ADR
$53.22 -0.91%
차트·분석 보기 → - 1GSK announced a roughly $2.52 billion cost-saving program primarily aimed at securing funding for late-stage clinical development
- 2The company will increase late-stage trials from about 10 to more than 20 by 2026, covering 7 assets and 18 indications
- 3With second-quarter results exceeding expectations, the move expands research before the 2028 patent expiration of HIV component dolutegravir
This 3-line summary is compiled from the report below.
Quartz +1 View original ↗🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다